Turalio OverviewPexidartinib (trade name Turalio; development code name PLX-3397) is a CSF1R antagonist drug created by Plexxikon. On 2 August 2019 it was approved by U.S. FDA for treatment of giant-cell tumor of the tendon sheath (GC-TS). References ^ Adis Insight drug profile: Pexidartinib ^ Microglial Magic: Drug Wipes Them Out, New Set Appears (PLX3397) ^ "FDA approves first therapy for rare joint tumor". FDA. 2 August 2...
Read more Turalio Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pexidartinib
Recent Turalio Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 200mg
NDC Database Records for Turalio: (1 result)Sorted by National Drug Code
- 65597-402 Turalio 200 mg Oral Capsule by Daiichi Sankyo Inc.